Company: BIAF
Filing Date: 2025-12-22
Form Type: 8-K
Source: 0001493152-25-028809
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-12-22
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

As
previously reported in a Current Report on Form 8-K (the “ Acquisition 8-K”) filed by bioAffinity Technologies, Inc. (the
“ Company”), on September 18, 2023, the Company’s wholly-owned subsidiary, Precision Pathology Laboratory Services LLC
(“ PPLS”), consummated the acquisition (the “ Acquisition”) of a clinical
anatomic and clinical pathology laboratory and related services business in San Antonio, Texas (the “ Laboratory Assets”)
pursuant to the terms of an Asset Purchase Agreement (the “ Asset Purchase Agreement”) dated September 18, 2023 that PPLS
entered into with Village Oaks Pathology Services, P. A., a Texas professional association d/b/a Precision Pathology Services (“ Village
Oaks Pathology”) and Dr. Roby P. Joyce, M. D. As reported in the Acquisition 8-K, in connection with the Asset Purchase Agreement,
PPLS entered into a Succession Agreement with Village Oaks Pathology and Dr. Joyce (the “ Joyce Succession Agreement”) pursuant
to which Dr. Joyce, as holder of 100% of the issued and outstanding stock of Village Oaks Pathology, is restricted from disposing of
his equity interests in Village Oaks Pathology, subject to certain exceptions, without the prior written consent of us and Village Oaks
Pathology. The Joyce Succession Agreement further named Dr. James Humphreys, who has served as a pathologist at PPLS since August, 2011
as a qualified and approved Successor (as such term is defined under the Joyce Separation Agreement) to Dr. Joyce.

In
December 2025, Dr. Joyce (77) informed the Company of his desire to transfer 100% of the issued
and outstanding stock of Village Oaks Pathology to Dr. Humphreys. Eligibility
Requirements of a Designated Physician (as such terms are defined and described in the Joyce Succession Agreement). is
restricted from disposing of his equity interests in Village Oaks Pathology, subject to certain exceptions, without the prior written
consent of us and Village Oaks Pathology. The Humphreys Succession Agreement further provides that the entire equity interest held by
Dr. Humphreys in Village Oaks Pathology will be automatically assigned and transferred to a successor who meets the Eligibility Requirements
of a Designated Physician (as such terms are defined and described in the Humphreys Succession